CollPlant announced the appointment of Revital Mandil-Levin as Chief Business Development Officer, effective immediately. In this position, Dr. Mandil-Levin will be responsible for business development initiatives aimed at leveraging the company's rhCollagen technology into new and emerging fields such as BioInk for 3D bioprinting of tissues and organs and aesthetics medicine, as well as expanding the reach of the company's marketed products, VergenixFG and VergenixSTR in existing and new territories. Before joining the company, from January 2014 to February 2018, Dr. Mandil-Levin served as Vice President Business Development at NeuroDerm Ltd.